Results 91 to 100 of about 108,380,509 (205)

Spotlight on the perioperative use of maropitant citrate

Veterinary Medicine: Research and Reports, 2017
Bonnie L Hay Kraus Department of Veterinary Clinical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, USA Abstract: Neurokinin-1 (NK-1) receptors are present in both the central nervous system and peripheral tissues. Substance P (
Hay Kraus BL
doaj  

The effect of substance P on asthmatic rat airway smooth muscle cell proliferation, migration, and cytoplasmic calcium concentration in vitro

Journal of Inflammation, 2011
Airway remodeling and airway hyper-responsiveness are prominent features of asthma. Neurogenic inflammation participates in the development of asthma. Neurokinin substance P acts by binding to neurokinin-1 receptor (NK-1R).
Wei Bing, Shang Yun-Xiao, Li Miao, Yang Yun-Gang   +3 more
doaj   +1 more source

Sustained endosomal release of a neurokinin-1 receptor antagonist from nanostars provides long-lasting relief of chronic pain. [PDF]

Biomaterials, 2022
Latorre R, Ramírez-Garcia PD, Hegron A, Grace JL, Retamal JS, Shenoy P, Tran M, Aurelio L, Flynn B, Poole DP, Klein-Cloud R, Jensen DD, Davis TP, Schmidt BL, Quinn JF, Whittaker MR, Veldhuis NA, Bunnett NW.   +17 more
europepmc   +1 more source

A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients. [PDF]

Support Care Cancer, 2022
Dranitsaris G, Moezi M, Dobson K, Phelan R, Blau S.   +4 more
europepmc   +1 more source

Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant

Drug Safety
Elinzanetant is a selective dual neurokinin (NK)-1/-3 receptor antagonist for the treatment of moderate-to-severe vasomotor symptoms associated with menopause or caused by endocrine therapy. Elinzanetant has been approved by health authorities in several countries.
James H. Lewis, Raúl J. Andrade, Dominique Larrey, Yves Horsmans, Richard A. Anderson, Mila Trajanovic, Esther Groettrup-Wolfers, Lineke Zuurman   +7 more
openaire   +3 more sources

Effects of neurokinin receptor antagonists in virus-infected airways

, 2000
We investigated the effects of a neurokinin-1 (NK1) receptor antagonist (SR-140333) and a NK2 receptor antagonist (SR-48968) on airway responsiveness and on the function of neuronal M2 muscarinic receptors, which normally inhibit vagal acetylcholine ...
David B. Jacoby, Bethany L. Yost, Thomas Elwood, Allison D. Fryer   +3 more
core   +1 more source

Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

Acta Dermato-Venereologica, 2019
The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs.
Athanasios Tsianakas, Claudia Zeidler, Claudia Riepe, Matthias Borowski, Caroline Forner, Joachim Gerss, Martin Metz, Petra Staubach, Ulrike Raap, Martin Kaatz, Marc Urban, Thomas A. Luger, Sonja Ständer   +12 more
doaj   +1 more source

Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial. [PDF]

J Eur Acad Dermatol Venereol, 2021
Welsh SE, Xiao C, Kaden AR, Brzezynski JL, Mohrman MA, Wang J, Smieszek SP, Przychodzen B, Ständer S, Polymeropoulos C, Birznieks G, Polymeropoulos MH.   +11 more
europepmc   +1 more source

Internalization of the neurokinin 1 receptor in rat myenteric neurons

, 1999
Internalization of the neurokinin 1 receptor in rat myenteric ...
BR Southwell (14473155), PT Mann (19457146), John Furness (13070439)   +2 more
core  

Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist. [PDF]

Asian Pac J Cancer Prev, 2022
Sukauichai S, Ketkaew C, Othaganont N, Pichaya P, Promsuwan P.   +4 more
europepmc   +1 more source